HC Wainwright cuts PTGX Q2 2025 earnings forecast

Summary

HC Wainwright adjusted its earnings expectations for Protagonist Therapeutics (NASDAQ: PTGX) for Q2 2025, lowering the EPS estimate from ($0.65) to ($0.67). The firm maintained a ‘Buy’ rating with a target price of $80.00 despite differing opinions from other analysts, such as Goldman Sachs and BMO Capital Markets. The stock opened at $43.04 with a market cap of $2.67 billion and has a 1-year price range between $27.00 and $60.60. The stock is heavily owned by institutional investors at 98.63%. Market Beat

Impact Analysis

The event is classified at the company level as it pertains specifically to Protagonist Therapeutics (PTGX). The downward revision of earnings expectations by HC Wainwright may signal anticipated challenges or slower growth for the company in the upcoming quarter, potentially influencing investor sentiment negatively. However, the ‘Buy’ rating suggests that the firm still sees long-term value. The disparity in target prices among analysts reflects uncertainty and differing perspectives on PTGX’s future performance. The stock’s substantial institutional ownership implies that it is closely watched by large investors, whose reactions can significantly impact the stock price. Furthermore, the broader market may perceive these mixed signals as a reason for caution, potentially leading to increased volatility in PTGX’s stock price. Investment opportunities could arise from understanding these dynamics and capitalizing on potential price fluctuations. Market Beat